ArticleInfectious Disease Modelling2025
Data fitting and optimal control strategies for HBV acute patient cases in the United States.
Article in Infectious Disease Modelling, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infection with Hepatitis B Virus (HBV) has been a serious public health issue worldwide. It caused more than one million fatalities per year. The mathematical modelling of the disease allows better understanding of the transmission of the disease and help the government policy makers to choose the best control strategies. With this inspiration, we proposed a novel dynamic model by incorporating infection-age structure to imitate the transmission of HBV, especially the age heterogeneity in horizontal and vertical (mother-to-child) transmission modes. We also discussed its impact on control measures and analyzed the dynamics of waning immunity and reinfection. We conducted sensitivity analysis to evaluate the effectiveness of each control measure. Our research concentrates on HBV acute patient cases in the United States data from Centre for Disease Control and Prevention (CDC). Our findings show that a mixed approach by including vaccination, medication and periodic health assessments can effectively control HBV transmission. Among these measures, we found that early vaccination with a single-dose vaccine of US$50 is the most cost-effective control strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.